Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gevokizumab + ramucirumab + paclitaxel
- Development stage
- Phase 1
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
gevokizumab + ramucirumab + paclitaxel is an investigational combination therapy consisting of three agents: gevokizumab (a recombinant monoclonal antibody targeting interleukin-1β), ramucirumab (a human IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor 2 [VEGFR2]), and paclitaxel (a chemotherapeutic taxane which promotes microtubule stabilization leading to mitotic arrest and apoptosis). The combination aims to attack tumors via complementary mechanisms: inhibition of angiogenesis (ramucirumab), suppression of pro-inflammatory cytokine signaling (gevokizumab), and direct cytotoxicity by microtubule stabilization (paclitaxel). This regimen is under study for advanced solid tumors, including gastric and gastroesophageal cancers.
- Brand names
- Taxol (paclitaxel)Cyramza (ramucirumab)
- Other names
- gevokizumabramucirumabpaclitaxel
02
Targets
IL1B (Interleukin-1 beta)VEGFR2 (Vascular endothelial growth factor receptor 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gevokizumab + ramucirumab + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gevokizumab + ramucirumab + paclitaxel.